Second CAR T cell therapy approved in China, Carteyva, for the treatment of r/r LBCL

The National Medical Products Administration (NMPA) of China has approved the New Drug Application (NDA) for JW Therapeutics’ anti-CD19 autologous chimeric antigen receptor T (CAR-T) cell immunotherapy product relmacabtagene autoleucel injection (hereafter abbreviated as relma-cel, R&D code JWCAR029) for the treatment of adult patients with relapsed or refractory large B-cell lymphoma (r/r LBCL) after two or more lines of systemic therapy, and has released the drug registration certificate. Relma-cel is the first CAR-T product approved as a Category 1 biologics product in China, and sixth approved CAR-T product globally.

  • The first CAR-T product independently developed in China and approved as a Category 1 biologics product, and the sixth approved CAR-T product globally

  • Currently the only approved CAR-T product that has been simultaneously included in the National Significant New Drug Development Program, granted priority review and breakthrough therapy designation

  • May provide a best-in-class CAR-T therapy in China given its demonstration of high rates of durable disease response and low rates of CAR-T associated toxicities

Relma-cel, JW Therapeutics’ inaugural CAR-T product, was independently developed utilizing the CAR T cell process platform of Juno Therapeutics, a subsidiary of Bristol Myers Squibb, to specifically address the requirements of the Chinese market. It currently stands as the sole approved CAR-T product in China simultaneously included in the National Significant New Drug Development Program, receiving priority review for relapsed or refractory large B-cell lymphoma (r/r LBCL) and breakthrough therapy designations for follicular lymphoma. With over 100 patients enrolled in clinical studies to date, relma-cel holds the distinction of being the most extensively studied anti-CD19 CAR-T product in China.

This approval is based on the results of a single-arm, multi-center, pivotal study (RELIANCE study) to evaluate the efficacy and safety of relma-cel in patients with relapsed or refractory large B-cell lymphoma (r/r LBCL) in China. RELIANCE study results show that relma-cel demonstrated high rates of durable disease response and low rates of CAR-T associated toxicities, and may provide a best-in-class CAR-T therapy profile.

Professor Zhu Jun, the lead investigator of RELIANCE study, Chief of Internal Medicine Department and Lymphoma Department at Peking University Cancer Hospital, said, “The RELIANCE study is a registrational clinical study completed with high quality, and I’m very proud of that. Based on the outstanding efficacy and safety profiles it demonstrated in RELIANCE study, I believe that relma-cel will provide healthcare professionals in China with an additional treatment option and bring hope for long-term remission and even cure for lymphoma patients.”

Edward Hu, Vice Chairman and Global Chief Investment Officer at WuXi AppTec, said, “Congratulations to JW Therapeutics for the approval of its first product. WuXi AppTec will continue to enable more companies to deliver advanced therapies for patients globally. Cell and gene therapy is one of the most promising therapies for curing cancer. As the co-founder and investor of JW Therapeutics, we are very pleased to witness its development over the past five years and are fully confident that JW Therapeutics will continue to lead the development of cell immunotherapy in China, and to bring us closer to a cure for cancer.”

Lynelle Hoch, senior vice president, Global Cell Therapy Franchise Lead, Bristol Myers Squibb, said, “As a long-standing strategic partner of JW Therapeutics, we are pleased by our work together to advance the important science of cell therapy. Today’s news, building from our CAR T cell process platform from Juno Therapeutics, marks an important milestone for patients in China and in achieving our shared goal of innovating breakthroughs for patients with cancer.”

James Li, Co-founder, Chairman and CEO of JW Therapeutics, said, “We sincerely thank all the patients and investigators who have participated and contributed in the clinical studies of relma-cel. We’re also encouraged by the Chinese regulators for taking the lead in following the science and approving the NDA of the sixth CAR-T therapy on a global scale. JW is committed to serving every Chinese patient through continued technology innovation.”

Share this article